Beyond Air, Inc. (XAIR)
Develops inhaled nitric oxide treatments for lung diseases and cancers.
$5.46+0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-90.5%
The outlook
XAIR is trading near its 52-week low with a Buy consensus from two analysts whose average target sits roughly 28x higher than the current price. The stock is below both its 50- and 200-day moving averages, reflecting weakness in recent momentum.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 2 analysts
Price trendBelow its 50- & 200-day averages
52-week range0% of the way from its 52-week low to high
Price targetAvg target +2830% vs current price
Analyst price target
~12-month · 2 analysts$160.00average target+2830.4% vs now
Now $5.46
Low $40.00High $280.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$3.9M
52-wk high
$95.60
52-wk low
$5.10
50-day avg
$8.00
200-day avg
$19.41
Trailing P/E
—